eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


5/2011
vol. 10
 
Share:
Share:
abstract:
Review paper

Mammographic breast density and hormonal therapy during postmenopause

Małgorzata Sobstyl
,
Joanna Tkaczuk-Włach
,
Grzegorz Jakiel

Przegląd Menopauzalny 2011; 5: 419–423
Online publish date: 2011/11/05
View full text Get citation
 
High criteria of mammographic breast density are the risk factor of breast cancer occurrence. Numerous research papers report that the estrogenic-progestagenic therapy, especially in continuous schema, results in nipple density increase up to 3-6%. Moreover, the literature states that the estrogenic therapy does not cause the increase of MBD. The type of gestagen used seems not to have any influence on breast density, however, estrogen dosage and the age at which the hormonal replacement therapy has been introduced, play crucial role. In most patients from the group of high risk of breast cancer and those treated because of this reason, the use of tamoxifen reduces statistically breast density. Other drugs such as raloxifene or letrozole indicate a decrease of mammographic breast density similar to placebo.
keywords:

mammographic breast density, breast cancer, hormonal therapy, tamoxifen, letrozole

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.